EACS2023: 832 Disruptions in testing and treatment services for hepatitis C virus during the SARS-CoV-2 epidemic among individuals with HIV susceptible for HCV reinfection: results from the EuroSIDA study A. Boyd , W. Bannister , C. Boesecke , A. Winston , C. Kenyon , M.-A. De Scheerder , I. Aho , H. Sambatakou , E. Devitt , F. Maltez , J.M. Llibre , P. Domingo , D.H. Reikvam , V.M Mitsura , J. Szlavik , E. Bakowska , E. Jablonowska , K. Zilmer M. Cavassini , G. Wandeler , A. Mocroft , L. Peters , for the EuroSIDA Study Stichting HIV Monitoring, Amsterdam, Netherlands, Rigshospitalet, University of Copenhagen, Centre of Excellence for Health, Immunity and Infections (CHIP), Copenhagen, Denmark, Department of Medicine I, University-Hospital Bonn, Bonn, Germany, Department of Infectious Disease, Imperial College London, London, United Kingdom, Institute of Tropical Medicine, Antwerp, Belgium, Ghent University Hospital, Ghent, Belgium, Division of Infectious Diseases, Helsinki University Hospital, Helsinki, Finland, Ippokration General Hospital, Athens, Greece, Department of Genitourinary Medicine and Infectious Diseases, St James's Hospital, Dublin, Ireland, Hospital Curry Cabral, Lisbon, Portugal, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Department of Infectious diseases, Oslo University Hospital, Oslo, Norway, Gomel State Medical University, Gomel, Belarus, South-Pest Hospital Centre – National Institute for Infectology and Haematology, Budapest, Hungary, Wojewodzki Szpital Zakazny, Warsaw, Poland, Clinic of Infectious Diseases and Hepatology, Medical University of Łódź, Łódź, Poland, West-Tallinn Central Hospital, Centre of Infectious Diseases, Tallinn, Estonia, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, United Kingdom General data Abstract category: Access and delivery of care Abstract body Purpose: We aimed to determine the effect of the SARS-CoV-2 epidemic on HCV testing and treatment in individuals with HIV across Europe, particularly in those with a previous HCV infection for whom the risk of HCV re-infection is substantially increased. Method: We included individuals with HIV followed in the EuroSIDA cohort study between January 2016-December 2021 who had a positive anti-HCV antibody test. For each calendar year between 2016-2021, we estimated the proportion of anti-HCV positive individuals who received an HCV-RNA test (both overall and in two subsets of individuals who were previously HCV-RNA negative because of [i] sustained virological response [SVR] or [ii] spontaneous clearance [SC]), as well as the proportion of individuals with a positive HCV-RNA test who commenced treatment with direct-acting antivirals (DAA) at any time during the year. Results: Between 2016-2021, 6126 individuals were at one point eligible to receive an HCV-RNA test. Overall (Figure 1A), the proportion tested during the year ranged between 32.8-39.4% in 2016-2019 and decreased slightly to 29.5% (n=1090/3700) in 2020 (p<0.001) and declined further to 26.6% ( n=861/3232) in 2021 (vs. 2020, p=0.008). The proportion tested for HCV-RNA in those who were HCV-RNA negative because of SVR and because of SC are shown in Figure 1B and Figure 1C, respectively. In those with a positive HCV-RNA result (Figure 1D), the proportion commencing DAA-therapy during the year ranged between 19.2%-24.6% in 2016-2019 and decreased significantly to 16.7% ( n=141/842) in 2020 ( p<0.001) and further to 13.3% ( n=80/600) in 2021 (vs. 2020, p=0.061). Figure 1. Conclusions: During the first year of the SARS-CoV-2 epidemic, there were declines in HCV testing for individuals susceptible to HCV reinfection and eligible for HCV-RNA testing and subsequent declines in the year thereafter. For those with chronic HCV, significant decreases in commencing DAA-treatment were also seen during the SARS-CoV-2 epidemic. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 2,21 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 49
RkJQdWJsaXNoZXIy Mzc2ODc=